MedTrace Logo

SGM-101 in Locally Advanced and Recurrent Rectal Cancer

NCT04642924 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 203

Last updated 2020-11-24

No results posted yet for this study

Summary

Near-infrared fluorescence-guided oncologic surgery (EGOS) with the use of a tumor specific tracer (SGM-101) developed by Surgimab can provide valuable intra-operative information about tumor location and extensiveness, which can be difficult to detect with conventional visual and tactile feedback. Hence, this information could aid in intra-operative decision making and therewith foster complete resection margins and less extensive surgery. Subsequently, this may drastically improve patient care by improving oncologic outcome.

Conditions

Interventions

DRUG

SGM-101

Fluorescence-guided surgery

Sponsors & Collaborators

  • Erasmus Medical Center

    collaborator OTHER

  • Amsterdam UMC, location VUmc

    collaborator OTHER

  • Catharina Ziekenhuis Eindhoven

    collaborator OTHER

  • Medical Center Haaglanden

    collaborator OTHER

  • Surgimab

    collaborator INDUSTRY

  • Quest Medical Imaging

    collaborator INDUSTRY

  • Centre for Human Drug Research, Netherlands

    collaborator OTHER

  • Leiden University Medical Center

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-22
Primary Completion
2021-10-31
Completion
2023-10-31

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04642924 on ClinicalTrials.gov